A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

June 7, 2022

Study Completion Date

June 7, 2022

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

ORMD-0801

8 mg capsules of ORMD-0801 (Oral Insulin)

OTHER

Placebo

Placebo capsule (Fish Oil)

Trial Locations (1)

Orange County Research Center (OCRC) 14351 Myford Rd., Suite B, Tustin, CA 92780, Tustin

All Listed Sponsors

lead

Oramed, Ltd.

INDUSTRY